High CR Rate with Cretostimogene for BCG-Failed Bladder Cancer
Cretostimogene showed high and durable responses in heavily pretreated BCG-unresponsive NMIBC with CIS in a phase 3 trial. Well-tolerated with minimal high-grade TRAEs.
Related Articles
AUA Annual Meeting
Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy for oncologists treating patients in a community setting.
TAR-200 Shows Durable Response in BCG-Unresponsive NMIBC: SunRISe-1 Cohort 2
Joseph Jacob, MD, discusses data from the phase 2b SunRISe-1 study, cohort 2, evaluating TAR-200 in BCG-unresponsive high-risk NMIBC with carcinoma in situ.
High CR Rate with Cretostimogene for BCG-Failed Bladder Cancer
Cretostimogene showed high and durable responses in heavily pretreated BCG-unresponsive NMIBC with CIS in a phase 3 trial. Well-tolerated with minimal high-grade TRAEs.
Predicting Cretostimogene Grenadenorepvec Response With Urinary Genomics
Colin P.N. Dinney, MD, discusses updated translational analyses from the BOND-003 and CORE-001 trials.
EVP With Consolidative Surgery Yields Promising Outcomes in Bladder Cancer
Enfortumab vedotin plus pembrolizumab followed by surgery showed high complete response rates in advanced urothelial cancer.
Younger Adults See Sharp Rise in Pancreas & Colon Cancer, Study Shows
Arvind Trindade, MD, discusses the background of a study investigating rates of pancreatic and colon cancer among younger patients.
Considering Therapy in a Patient With Myelofibrosis Eligible for Transplant
During a live event, Mark J. Fesler, MD, and participants discuss next steps for a 68-year-old patient with intermediate-risk myelofibrosis.
Study Reaffirms Favorable Outcomes for Small Papillary Thyroid Cancers
A small papillary thyroid cancer study demonstrates favorable outcomes and highlights the role of American Thyroid Association risk stratification.
Ruxolitinib Therapy for cGVHD: Insights on Patient and Safety Monitoring
A panelist discusses how managing adverse events (AEs) in patients with chronic graft-vs-host disease (cGVHD) treated with ruxolitinib requires a structured monitoring approach that balances…
SC Pembrolizumab Noninferior to IV in NSCLC: Phase 3 Trial Results
Enriqueta Felip, MD, PhD, discusses the 3475A-D77 trial of subcutaneous pembrolizumab vs intravenous pembrolizumab plus chemotherapy in metastatic NSCLC.